Tackling the cancer signal transduction "labyrinth": A combinatorial use of biochemical tools with mathematical models will enhance the identification of optimal targets for each molecular defect

Cancer

Volumn 120, Issue 3, 2014, Pages 316-322

  Karamouzis, Michalis V ^a   Papavassiliou, Athanasios G ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

biochemistry; cancer treatment; computational oncology; epidermal growth factor receptor; mathematical modeling; signal transduction; targeted agents

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4;

CANCER RESEARCH; DOWN REGULATION; FEEDBACK SYSTEM; GENOMICS; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MATHEMATICAL MODEL; MOLECULAR DOCKING; MOLECULAR EVOLUTION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN STABILITY; PROTEOMICS; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION;

HUMANS; MODELS, THEORETICAL; NEOPLASMS; PROTEOMICS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION;

EID: 84892917593     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28424     Document Type: Review

References (60)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2013. CA Cancer J Clin. 2013; 63: 11-30.
2. Karamouzis MV, Papavassiliou AG,. Transcription factor networks as targets for therapeutic intervention of cancer: the breast cancer paradigm. Mol Med. 2011; 17: 1133-1136.
3. Nguyen LV, Vanner R, Dirks P, Eaves CJ,. Cancer stem cells: an evolving concept. Nat Rev Cancer. 2012; 12: 133-143.
4. Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG,. Targeting post-translational modifications and functional regulation of the Ras superfamily of small G-proteins for anticancer drug development. Nat Rev Drugs Discov. 2007; 6: 541-555.
5. Baer C, Claus R, Plass C,. Genome-wide epigenetic regulation of miRNAs in cancer. Cancer Res. 2013; 73: 473-477.
6. Neuert G, Munsky B, Tan RZ, Teytelman L, Khammash M, van Oudenaarden A,. Systematic identification of signal-activated stochastic gene regulation. Science. 2013; 339: 584-587.
7. Morrissey JP, Hassmiller L, Price RA, Mandelblatt J,. Computational modeling and multilevel cancer control interventions. J Natl Cancer Inst Monogr. 2012; 44: 56-66.
8. Byrne HM,. Dissecting cancer through mathematics: from the cell to the animal model. Nat Rev Cancer. 2010; 10: 221-230.
9. Ovaa H, van Leeuwen F,. Chemical biology approaches to probe the proteome. Chembiochem. 2008; 9: 2913-2919.
10. Rogne M, Taskén K,. Cell signaling analyses in the functional genomics era. N Biotechnol. 2013; 30: 333-338.
11. Folger O, Jerby L, Frezza C, Gottlieb E, Ruppin E, Shlomi T,. Predicting selective drug targets in cancer through metabolic networks. Mol Syst Biol. 2011; 7: 501.
12. Eglen RM, Reisine T,. Screening for compounds that modulate epigenetic regulation of the transcriptome: an overview. J Biomol Screen. 2011; 16: 1137-1152.
13. Scatena R, Bottoni P, Pontoglio A, Giardina B,. The proteomics of cancer stem cells: potential clinical applications for innovative research in oncology. Proteomics Clin Appl. 2011; 5: 590-602.
14. Sun X, Zhang L, Tan H, Bao J, Strouthos C, Zhou X,. Multi-scale agent-based brain cancer modelling and prediction of TKI treatment response: incorporating EGFR signalling pathway and angiogenesis. BMC Bioinformatics. 2012; 13: 218.
15. Tang J, Aittokallio T,. Network pharmacology strategies toward multi-target anticancer therapies: from computational models to experimental design principles. Curr Pharm Des. 2013;doi: 10.2174/13816128113199990470.
16. Morris MK, Melas I, Saez-Rodriguez J,. Construction of cell type-specific logic models of signaling networks using CellNOpt. Methods Mol Biol. 2013; 930: 179-214.
17. Liu J, Lee W, Jiang Z, Chen Z, Jhunjhunwala S, Haverty PM, et al. Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events. Genome Res. 2012; 22: 2315-2327.
18. Lefor AT,. Computational oncology. Jpn J Clin Oncol. 2011; 41: 937-947.
19. Winslow RL, Trayanova N, Geman D, Miller MI,. Computational medicine: translating models to clinical care. Sci Transl Med. 2012; 4: 158rv11.
20. Brodland GW, Veldhuis JH,. The mechanics of metastasis: insights from a computational model. PLoS One. 2012; 7: e44281.
21. Schlüter DK, Ramis-Conde I, Chaplain MA,. Computational modelling of single-cell migration: the leading role of extracellular matrix fibers. Biophys J. 2012; 103: 1141-1151.
22. Bajikar SS, Janes KA,. Multiscale models of cell signalling. Ann Biomed Eng. 2012; 40: 2319-2327.
23. MacConaill LE,. Existing and emerging technologies for tumor genomic profiling. J Clin Oncol. 2013; 31: 1815-1824.
24. Peifer M, Fernández-Cuesta L, Sos ML, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet. 2012; 44: 1104-1110.
25. Vignot S, Frampton GM, Soria JC, et al. Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer. J Clin Oncol. 2013; 31: 2167-2172.
26. Van Allen EM, Wagle N, Levy MA,. Clinical analysis and interpretation of cancer genome data. J Clin Oncol. 2013; 31: 1825-1833.
27. Chaudhary SU, Shin SY, Lee D, Song JH, Cho KH,. ELECANS - an integrated model development environment for multiscale cancer systems biology. Bioinformatics. 2013; 29: 957-959.
28. Bentley K, Jones M, Cruys B,. Predicting the future: towards symbiotic computational and experimental angiogenesis research, Exp Cell Res. 2013; 319: 1240-1246.
29. Stites EC,. Chemical kinetic mechanistic models to investigate cancer biology and impact cancer medicine. Phys Biol. 2013; 10: 026004.
30. Bedard PL, Oza AM, Tsao MS, et al. Princess Margaret Cancer Centre (PMCC) Integrated Molecular Profiling in Advanced Cancers Trial (IMPACT) using genotyping and targeted next-generation sequencing (NGS) [abstract]. J Clin Oncol. 2013; 31 (suppl): abstract 11002.
31. Liang S, Chandra P, Ma Z, et al. A community-based program for personalized cancer care using next-generation sequencing (NGS) [abstract]. J Clin Oncol. 2013; 31 (suppl): abstract 11102.
32. Hollebecque A, Massard C, De Baere T, et al. Molecular screening for cancer treatment optimization (MOSCATO 01): A prospective molecular triage trial-Interim results [abstract]. J Clin Oncol. 2013; 13 (suppl): abstract 2512.
33. Meric-Bernstam F, Farhangfar C, Mendelsohn J, Mills GB,. Building a personalized medicine infrastructure at a major cancer center. J Clin Oncol. 2013; 31: 1849-1857.
34. Dienstmann R, Rodon J, Barretina Tabernero J,. Genomic medicine frontier in human solid tumors: prospects and challenges. J Clin Oncol. 2013; 13: 1874-1884.
35. Karamouzis MV, Grandis JR, Argiris A,. Therapies against epidermal growth factor receptor in aerodigestive carcinomas. JAMA. 2007; 298: 70-82.
36. Hudis CA,. Trastuzumab - mechanism of action and use in clinical practice. N Engl J Med. 2007; 357: 39-51.
37. Gargalionis AN, Karamouzis MV, Papavassiliou AG,. The molecular rationale of Src inhibition in colorectal carcinomas. Int J Cancer. 2013;doi: 10.1002/ijc.28299.
38. Barlesi F, Blons H, Beau-Faller M, et al. Biomarkers (BM) France: Results of routine EGFR, HER2, KRAS, BRAF, PI3KCA mutations detection and EML4-ALK gene fusion assessment on the first 10,000 non-small cell lung cancer (NSCLC) patients (pts) [abstract]. J Clin Oncol. 2013; 13 (suppl): abstract 8000.
39. Oliner KS, Douillard JY, Siena S, et al. Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC) [abstract]. J Clin Oncol. 2013; 31 (suppl): abstract 3511.
40. Sosman JA, Daud A, Weber JS, et al. BRAF inhibitor (BRAFi) dabrafenib in combination with the MEK1/2 inhibitor (MEKi) trametinib in BRAFi-naive and BRAFi-resistant patients (pts) with BRAF mutation-positive metastatic melanoma (MM) [abstract]. J Clin Oncol. 2013; 31 (suppl): abstract 9005.
41. Karamouzis MV, Konstantinopoulos PA, Papavassiliou AG,. Targeting c-Met as a strategy to overcome cross-talk related resistance to EGFR protein-targeting agents in cancer therapeutics. Lancet Oncol. 2009; 10: 709-717.
42. Karamouzis MV, Konstantinopoulos PA, Papavassiliou AG,. Trastuzumab - mechanism of action and use. N Engl J Med. 2007; 357: 1664-1666.
43. Bardelli A, Corso S, Bertotti A, et al. Amplification of the MET receptor to drive resistance to anti-EGFR therapies in colorectal cancer [abstract]. J Clin Oncol. 2013; 31 (suppl): abstract 11005.
44. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N,. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 2010; 464: 427-430.
45. Hatzivassiliou G, Song K, Yen I, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature. 2010; 464: 431-435.
46. Heidorn SJ, Milagre C, Whittaker S, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell. 2010; 140: 209-221.
47. Birtwistle MR, Hatakeyama M, Yumoto N, Ogunnaike BA, Hoek JB, Kholodenko BN,. Ligand-dependent responses of the ERBB signaling network: experimental and modeling analyses. Mol Syst Biol. 2007; 3: 144.
48. Riley L, Zhou H, Lange K, Sinsheimer JS, Sehl ME,. Determining duration of HER2-targeted therapy using stem cell extinction models. PLoS One. 2012; 7: e46613.
49. Park YH, Jung HA, Chang WJ, et al. Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) patients who received taxane plus trastuzumab treatment [abstract]. J Clin Oncol. 2013; 31 (suppl): abstract 637.
50. Karamouzis MV, Dalagiorgou G, Perez SA,., Georgopoulou U, Papavassiliou AG,. Targeting low-expressing ERBB-2 and acquired resistant high-expressing ERBB-2 breast carcinomas [abstract]. J Clin Oncol. 2013; 31 (suppl): abstract e11513.
51. Bartsch R, Berghoff AS, Bago-Horvath Z, et al. Coexpression of HER3 as a predictor of survival in HER2-positive breast cancer patients [abstract]. J Clin Oncol. 2013; 31 (suppl): abstract 611.
52. Bianconi F, Baldelli E, Ludovini V, Crinò L, Flacco A, Valigi P,. Computational model of EGFR and IGFR1 pathways in lung cancer: a systems biology approach for translational oncology. Biotechnol Adv. 2012; 30: 142-153.
53. Chia SKL, Ellard S, Mates M, et al. A phase Ib study of an anti-HER2 inhibitor, lapatinib, in combination with a c-MET and VEGFR inhibitor, foretinib, in HER2-positive metastatic breast cancer (MBC): Results from NCIC CTG IND.198 [abstract]. J Clin Oncol. 2013; 31 (suppl): abstract 518.
54. Schoeberl B, Pace EA, Fitzgerald JB, Harms BD, Xu L, Nie L, et al. Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis. Sci Signal. 2009; 2: 1-14.
55. Schoeberl B, Faber AC, Li D, et al. An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. Cancer Res. 2010; 70: 2485-2494.
56. Arnedos M, Denlinger CS, Harb WA, et al. A phase I study of MM-121 in combination with multiple anticancer therapies in patients with advanced solid tumors [abstract]. J Clin Oncol. 2013; 31 (suppl): abstract 2609.
57. Pedicini P, Caivano R, Jereczek-Fossa BA, et al. Modelling the correlation between EGFR expression and tumour cell radiosensitivity, and combined treatments of radiation and monoclonal antibody EGFR inhibitors. Theor Biol Med Model. 2012; 9: 23.
58. Dixit A, Verkhivker GM,. Computational modeling of allosteric communication reveals organizing principles of mutation-induced signalling in ABL and EGFR kinases. PLoS Comput Biol. 2011; 7: 1002179.
59. Weissman JS, Giannikopoulos P, John JS, et al. Integrated genomic analysis by whole exome and transcriptome sequencing of tumor samples from EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p) with acquired resistance to erlotinib [abstract]. J Clin Oncol. 2013; 31 (suppl): abstract 11010.
60. Lazzari C, Novello S, Barni S, et al. Randomized proteomic stratified phase III study of second-line erlotinib (E) versus chemotherapy (CT) in patients with inoperable non-small cell lung cancer (PROSE) [abstract]. J Clin Oncol. 2013; 31 (suppl): abstract LBA8005.